Scarring alopecia as an unexpected consequence of immune checkpoint inhibition

By afschroeder • June 18, 2025

Kokikian N, Tarabay J, Goh C. Scarring alopecia as an unexpected consequence of immune checkpoint inhibition. JAAD Case Rep. 2025 May 8;61:1-6. doi: 10.1016/j.jdcr.2025.04.007. PMID: 40530179; PMCID: PMC12173679.

Tags: Alopecia, Dermatology, immune checkpoint inhibitor, PD-1 inhibitor, pembrolizumab, Publications, scarring alopecia

Systemic Corticosteroid Exposure in Patients with Atopic Dermatitis: A US Population-Based Study

Bunick CG, Vleugels RA, Lebwohl M, Armstrong AW, Grada A, Yue EX, Saranadasa M, Wegrzyn L, D'Andrea E. Systemic Corticosteroid Exposure in Patients with Atopic[...]

Onset and depth of response with abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis, including prominent head-and-neck dermatitis: A post hoc analysis of the head-to-head phase 3 JADE DARE study

Armstrong AW, Gooderham MJ, Eyerich K, Reich K, Blauvelt A, Hong HC, Edwards RA, Bonfanti G, Clibborn C, Biswas P, Chan G, Feeney C, Güler[...]

AI and Digital Tools in Dermatology: Addressing Access and Misinformation

du Crest D, Madhumita M, Enbiale W, Ruiz Postigo JA, Malvehy J, Wongvibulsin S, Gupta S, Kittler H, Skayem C, Mahto A, Adamson AS, Lipoff[...]